Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 1/20 | 0.60 |
| ▸ | GRM6 | O15303 | 1/20 | 0.60 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.60 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.60 |
| ▸ | GSR | P00390 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.60 |
| ▸ | GRM5 | P41594 | 1/20 | 0.60 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.60 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.60 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.60 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.60 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.60 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.60 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.60 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.60 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.60 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.60 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.60 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22502695 | 1.00 | GRM8 (0.60) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL29831114 | 1.00 | GRM8 (0.60) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL4959221 | 0.88 | GRM8 (0.62) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL496858 | 0.88 | GRM8 (0.62) | GRM8GRM6GRIN2DGRIN3BGSR | |
| Hydrochloric Acid SCHEMBL10636419 | 0.86 | GRM8 (0.60) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL1332165 | 0.85 | ENPEP (0.50) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL435290 | 0.84 | GRM8 (0.58) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL2917215 | 0.84 | GRM8 (0.58) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL27276881 | 0.84 | ALDH1A1 (0.50) | GRM8GRM6GRIN2DGRIN3BGSR | |
| Glutamic Acid SCHEMBL27871403 | 0.83 | GSR (0.62) | GRM8GRM6GRIN2DGRIN3BGSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200270202-A1 | POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE | THE UNIVERSITY OF TOLEDO (US) | 2020-08-27 | — | — | US | claimed |
| WO-2017172476-A1 | POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE | THE UNIVERSITY OF TOLEDO (US) | 2017-10-05 | — | — | WO | claimed |
| US-20060058221-A1 | Baclofen conjugate and a pharmaceutical composition for treatment of neuronal disorders | MILLER LANDON C | 2006-03-16 | — | — | US | claimed |
| US-20260137678-A1 | METHODS FOR TREATING OR PREVENTING NEUROENDOCRINE TUMOR FORMATION USING XPO1 INHIBITORS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2025015030-A1 | PEPTIDE HYDROGELS, COMPOSITIONS, AND CONDITIONS FOR SCALABLE 3D CELL MANUFACTURING AND APPLICATIONS | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2025-01-16 | — | — | WO | disclosed |
| US-20240228962-A9 | METHODS FOR EXPANDING REGULATORY T CELLS | KSQ Therapeutics, Inc. | 2024-07-11 | — | — | US | disclosed |
| WO-2024086562-A2 | METHODS FOR TREATING OR PREVENTING NEUROENDOCRINE TUMOR FORMATION USING XPO1 INHIBITORS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20240132843-A1 | METHODS FOR EXPANDING REGULATORY T CELLS | KSQ THERAPEUTICS INC (US) | 2024-04-25 | — | — | US | disclosed |
| EP-4297757-A1 | METHODS FOR EXPANDING REGULATORY T CELLS | KSQ Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| US-11773357-B2 | Perfusion plate for microarray 3D bioprinting | CLEVELAND STATE UNIVERSITY (US) | 2023-10-03 | — | — | US | disclosed |
| EP-4171237-A1 | USE OF AN ORGANO-MINERAL COMPOSITION VIA FOLIAR APPLICATION TO STIMULATE PLANT DEVELOPMENT IN THE PRESENCE OF AT LEAST ONE ABIOTIC STRESS OR BIOTIC STRESS | Olmix (FR) | 2023-05-03 | — | — | EP | disclosed |
| US-20200270202-A1 | POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE | THE UNIVERSITY OF TOLEDO (US) | 2020-08-27 | — | — | US | disclosed |
| CN-104945345-B | The preparation method of chiral morpholine class compound and the preparation method of chiral amino acids compound | 深圳市海王英特龙生物技术股份有限公司 | 2017-11-21 | — | — | CN | disclosed |
| WO-2017172476-A1 | POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE | THE UNIVERSITY OF TOLEDO (US) | 2017-10-05 | — | — | WO | disclosed |
| US-7157421-B2 | Piracetam and piracetam analog conjugate and a pharmaceutical composition for treatment of neuronal disorders | MILLER LANDON C G | 2007-01-02 | — | — | US | disclosed |
| US-7157421-B2 | Piracetam and piracetam analog conjugate and a pharmaceutical composition for treatment of neuronal disorders | MILLER LANDON C G | 2007-01-02 | — | — | US | disclosed |
| US-7074775-B2 | Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders | MILLER LANDON C G | 2006-07-11 | — | — | US | disclosed |
| US-20060142182-A1 | Piracetam and piracetam analog conjugate and a pharmaceutical composition for treatment of neuronal disorders | MILLER LANDON C | 2006-06-29 | — | — | US | disclosed |
| US-20060142182-A1 | Piracetam and piracetam analog conjugate and a pharmaceutical composition for treatment of neuronal disorders | MILLER LANDON C | 2006-06-29 | — | — | US | disclosed |
| US-20060058219-A1 | Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders | MILLER LANDON C | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142182-A1 | Piracetam and piracetam analog conjugate and a pharmaceutical composition for treatment of neuronal disorders | PRLHR, GIPR, NTSR1 | GRM8 587/4885GRM6 22/4885GRIN2D 647/4885 |
| US-20260137678-A1 | METHODS FOR TREATING OR PREVENTING NEUROENDOCRINE TUMOR FORMATION USING XPO1 INHIBITORS | RB1, ERCC4, TP53 | GRM8 1453/4885GRM6 3174/4885GRIN2D 4082/4885 |
| US-20200270202-A1 | POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE | GOT1, ACAT1, GOT2 | GRM8 4111/4885GRM6 3615/4885GRIN2D 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.